eFFECTOR Therapeutics Stock

effector.comBioTechFounded: 2012Funding to Date: $168.82MM

eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs).

Register for Details

For more details on financing and valuation for eFFECTOR Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Stephen Worland Ph.D
Chief Executive Officer, President, Board Member & Co-Founder
Alana McNulty
Chief Financial Officer
Siegfried Reich Ph.D
Senior Vice President, Research & Co-Founder
Davide Ruggero Ph.D
Co-Founder
Annette Matthies Ph.D
Vice President of Corporate Development
Debra Vallner Ph.D
Vice President of Development Operations
Jeremy Barton MD
Chief Medical Officer
Kevan Shokat Ph.D
Co-Founder and Member of Scientific Advisory Board
Kevin Webster Ph.D
Senior Vice President of Cancer Biology

Board Members

David Maki JD
Altitude Life Science Ventures
Elaine Jones Ph.D
Pfizer Ventures
Jonathan Root MD
US Venture Partners
Ken Haas JD
KT Moortgat Ph.D
AbbVie Ventures
Laurence Lasky Ph.D
US Venture Partners
Markus Goebel Ph.D
Novartis Venture Fund
Simeon George MD
SR One
Stephen Worland Ph.D

Other companies like eFFECTOR Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM
Sector
Last Round Est. Valuation
$289.42MM

News

Locust Walk Acquisition Corp. (NASDAQ: LWAC) (“LWAC” or the “Company”), a special purpose acquisition company, announced today that the Company’s stockholders have approved all proposals related to the previously announced business combination (the “Business Combination”) with eFFECTOR Therapeutics, Inc. (“eFFECTOR”) at a special meeting of stockholders held on August 24, 2021. Approximately 93.2% of the votes cast at the meeting on the Business Combination proposal, representing approximately 71.7% of LWAC’s outstanding shares, voted to approve the Business Combination.
San Diego’s Effector Therapeutics, a five-year-old cancer drug developer, has raised $38.6 million in new venture capital funding. The Series C financing,
/PRNewswire/ -- eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today...